2026 Updates in Ketamine-Assisted Mental Health Care
The ketamine-assisted mental health care landscape looks considerably different in 2026 than it did five years ago. What was once a niche intervention offered by a small number of specialized clinics has expanded into a more organized field, with growing evidence, more experienced providers, and clearer — though still evolving — regulatory and payer frameworks. This post summarizes key developments and their practical implications for clinicians.
Where the Evidence Stands
The evidence base for ketamine in treatment-resistant depression has continued to grow. Spravato (esketamine), FDA-approved in 2019, now has several years of real-world use data alongside its original clinical trial evidence. Many patients and clinicians report outcomes that align broadly with the trial data: meaningful symptom reduction in a substantial portion of patients with TRD, with faster onset than traditional antidepressants.
IV ketamine’s evidence base, while still off-label, has also expanded. A number of observational studies and retrospective analyses from specialized centers have been published, contributing to a more nuanced picture of who responds, who doesn’t, and what factors predict durability of response. The literature consistently identifies that ketamine produces rapid effects — within hours to days — and that maintenance dosing is often necessary to sustain them.
The anxiety comorbidity picture is worth noting. Many patients with treatment-resistant depression carry comorbid generalized anxiety disorder (ICD-10 F41.1) or other anxiety presentations. Some clinicians report that ketamine’s effects extend to anxiety symptoms, though the evidence here is less consolidated than for depression. Patients with this dual presentation warrant careful monitoring of both symptom dimensions across the treatment course.
Researchers are also exploring ketamine in PTSD, OCD, and certain pain conditions. Clinicians should be aware that referrals for these indications are off-label and that the evidence, while interesting, is at earlier stages.
Regulatory and Payer Context in 2026
The regulatory structure for Spravato remains centered on the REMS program. Every facility administering Spravato must be certified through the REMS, every prescriber must be enrolled, and every patient must consent and be monitored for the mandatory two hours post-dose. This structure has not changed, and REMS compliance remains a non-negotiable element of any Spravato program. The REMS ensures uniform safety standards across the growing number of certified sites.
On the payer side, the Medicare Part B coverage framework for Spravato (using HCPCS S0013 for the drug and G2082/G2083 for administration) is now well-established. Commercial coverage has become more consistent, with many large national insurers maintaining published Spravato coverage policies that specify documentation requirements and criteria — typically two failed antidepressant trials at adequate dose and duration.
Medicaid coverage remains heterogeneous by state. States that have adopted Spravato coverage policies generally require prior authorization with documentation of treatment-resistant depression. Clinicians treating Medicaid-enrolled patients should verify state-specific criteria before initiating treatment and factor potential authorization timelines into their scheduling.
Telehealth prescribing of controlled substances — a regulatory area that shifted considerably during and after the public health emergency — has direct implications for ketamine program operations. Clinicians should stay current on DEA requirements for Schedule III substances (racemic ketamine) and the specific rules around Spravato’s prescribing, which requires at least an initial in-person evaluation.
Practice Considerations for 2026
Several practical themes are shaping how well-run ketamine programs operate this year.
Integration with psychotherapy. The evidence and clinical consensus have moved toward ketamine as one element of a broader treatment plan, not a stand-alone intervention. Programs that combine ketamine sessions with structured psychotherapy — whether CBT, ACE, or other modalities — report that patients often derive more durable benefit. Clinicians who do not provide psychotherapy themselves should establish clear referral relationships with licensed therapists who are familiar with ketamine treatment so patients can access this adjunctive support.
Screening and exclusion criteria. Systematic pre-treatment screening has become standard practice at experienced programs. This includes screening for personal or family history of psychosis, current manic or hypomanic symptoms, active substance use disorders, cardiovascular risk factors, and bladder health (relevant primarily for long-term high-dose racemic ketamine). A thorough psychiatric evaluation (CPT 90791) is the foundation. Programs that skip this step face higher rates of adverse events and complicated treatment courses.
Outcome tracking. Using validated instruments — PHQ-9, GAD-7, or Columbia Suicide Severity Rating Scale as appropriate — at baseline and at regular intervals provides objective data that supports treatment decisions, demonstrates medical necessity for ongoing sessions, and contributes to the broader evidence base. Many programs are now submitting de-identified outcome data to registries, which supports field-wide learning.
Referral network development. Primary care physicians, nurse practitioners, and non-prescribing therapists are increasingly aware of ketamine-based options and are asking how to refer. Clinicians operating ketamine programs benefit from investing in clear, accessible educational materials for referring providers that outline criteria, the evaluation process, and what to expect.
The SAMHSA treatment locator and clinical resources provide useful publicly accessible information on behavioral health treatment frameworks that complement the clinical picture for patients and referring providers.
As the field matures, clinicians who invest in rigorous patient selection, outcome monitoring, and multidisciplinary integration are best positioned to deliver durable benefit. Connect with our team to discuss clinical collaboration or to inquire about our approach to ketamine-assisted care.
This content is for educational purposes only and does not constitute medical advice. Consult a licensed clinician about your specific situation.
Drafted by AI and reviewed by our editorial team. Last updated 2026-05-30.